PremiumThe FlyEditas Medicine price target lowered to $4 from $8 at Baird Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing PremiumThe FlyLargest borrow rate increases among liquid names Cognex, Editas, Akebia, Tvardi, Chipotle: Trending by Analysts Editas Medicine initiated with a Buy at H.C. Wainwright PremiumThe FlyEditas Medicine CFO Erick Lucera to step down, Amy Parison to succeed Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones Biotech Alert: Searches spiking for these stocks today 
